(A) Agilent Technologies - Ratings and Ratios
Chromatography, Spectrometry, Genomics, Diagnostics, Services
A EPS (Earnings per Share)
A Revenue
Description: A Agilent Technologies September 29, 2025
Agilent Technologies (NYSE:A) delivers application-focused analytical and diagnostic solutions across three operating segments: Life Sciences & Applied Markets, Diagnostics & Genomics, and Agilent CrossLab. The company, incorporated in 1999 and headquartered in Santa Clara, California, serves global customers through a mix of direct sales, distributors, and electronic commerce.
The Life Sciences & Applied Markets segment provides a broad portfolio of chromatography (LC, GC) and mass-spectrometry systems, a suite of elemental analysis instruments (ICP-MS, AAS, ICP-OES, MP-AES), Raman spectroscopy, laboratory software, automation, and related consumables such as columns, sample-prep kits, and vacuum pumps. This breadth supports drug discovery, environmental testing, and materials research.
Diagnostics & Genomics focuses on genomics services, contract manufacturing, pathology, companion diagnostics, and biomolecular analysis, alongside cell-analysis platforms (flow cytometers, real-time cell analyzers, imaging systems, microplate readers) and their consumables. These offerings address precision medicine, clinical trials, and biotech R&D.
Agilent CrossLab delivers aftermarket and professional services-including repairs, maintenance, training, compliance support, SaaS analytics, asset management, and consulting-helping customers maximize instrument uptime and data integrity.
**Additional context:** (1) FY 2024 revenue reached approximately **$7.2 billion**, with a **5-6 %** year-over-year growth driven largely by the Life Sciences segment’s expansion in chromatography and mass-spec sales. (2) R&D intensity remains high at **~10 % of revenue**, reflecting the need to stay ahead in high-resolution analytical technologies. (3) Macro-level demand is underpinned by continued biotech capital spending, which the **Life Sciences Tools & Services** sub-industry tracks at a **~8 % CAGR** globally, and by increasing regulatory scrutiny that fuels the Diagnostics & Genomics service market.
For a deeper quantitative view of Agilent’s valuation metrics and scenario analysis, the ValueRay platform offers a transparent model worth exploring.
A Stock Overview
| Market Cap in USD | 39,591m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 1999-11-18 |
A Stock Ratings
| Growth Rating | -0.04% |
| Fundamental | 64.8% |
| Dividend Rating | 58.2% |
| Return 12m vs S&P 500 | -5.92% |
| Analyst Rating | 4.0 of 5 |
A Dividends
| Dividend Yield 12m | 0.68% |
| Yield on Cost 5y | 1.01% |
| Annual Growth 5y | 15.35% |
| Payout Consistency | 67.2% |
| Payout Ratio | 18.2% |
A Growth Ratios
| Growth Correlation 3m | 92.3% |
| Growth Correlation 12m | -28.6% |
| Growth Correlation 5y | -8.3% |
| CAGR 5y | 2.72% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.07 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.16 |
| Sharpe Ratio 12m | -0.07 |
| Alpha | -13.05 |
| Beta | 1.262 |
| Volatility | 27.29% |
| Current Volume | 1187.9k |
| Average Volume 20d | 1538.4k |
| Stop Loss | 142.1 (-3.1%) |
| Signal | 0.23 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (1.22b TTM) > 0 and > 6% of Revenue (6% = 407.3m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA -1.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 34.78% (prev 28.74%; Δ 6.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 1.50b > Net Income 1.22b (YES >=105%, WARN >=100%) |
| Net Debt (1.87b) to EBITDA (1.80b) ratio: 1.04 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.25 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (285.0m) change vs 12m ago -2.06% (target <= -2.0% for YES) |
| Gross Margin 52.96% (prev 54.39%; Δ -1.43pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 58.46% (prev 59.09%; Δ -0.62pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.91 (EBITDA TTM 1.80b / Interest Expense TTM 117.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.58
| (A) 0.19 = (Total Current Assets 4.25b - Total Current Liabilities 1.89b) / Total Assets 12.23b |
| (B) 0.09 = Retained Earnings (Balance) 1.10b / Total Assets 12.23b |
| (C) 0.13 = EBIT TTM 1.51b / Avg Total Assets 11.61b |
| (D) 0.14 = Book Value of Equity 822.0m / Total Liabilities 5.86b |
| Total Rating: 2.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.82
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 3.38% = 1.69 |
| 3. FCF Margin 20.65% = 5.16 |
| 4. Debt/Equity 0.54 = 2.36 |
| 5. Debt/Ebitda 1.04 = 1.71 |
| 6. ROIC - WACC (= 4.68)% = 5.85 |
| 7. RoE 19.97% = 1.66 |
| 8. Rev. Trend -42.00% = -3.15 |
| 9. EPS Trend -29.51% = -1.48 |
What is the price of A shares?
Over the past week, the price has changed by +2.51%, over one month by +18.69%, over three months by +22.87% and over the past year by +12.35%.
Is Agilent Technologies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of A is around 129.73 USD . This means that A is currently overvalued and has a potential downside of -11.5%.
Is A a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the A price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 148.6 | 1.4% |
| Analysts Target Price | 148.6 | 1.4% |
| ValueRay Target Price | 146.4 | -0.1% |
A Fundamental Data Overview October 17, 2025
P/E Trailing = 32.6285
P/E Forward = 22.9358
P/S = 5.8325
P/B = 6.1729
P/EG = 2.1628
Beta = 1.262
Revenue TTM = 6.79b USD
EBIT TTM = 1.51b USD
EBITDA TTM = 1.80b USD
Long Term Debt = 3.35b USD (from longTermDebt, last quarter)
Short Term Debt = 59.0m USD (from shortTermDebt, last quarter)
Debt = 3.41b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.87b USD (from netDebt column, last quarter)
Enterprise Value = 41.46b USD (39.59b + Debt 3.41b - CCE 1.53b)
Interest Coverage Ratio = 12.91 (Ebit TTM 1.51b / Interest Expense TTM 117.0m)
FCF Yield = 3.38% (FCF TTM 1.40b / Enterprise Value 41.46b)
FCF Margin = 20.65% (FCF TTM 1.40b / Revenue TTM 6.79b)
Net Margin = 17.97% (Net Income TTM 1.22b / Revenue TTM 6.79b)
Gross Margin = 52.96% ((Revenue TTM 6.79b - Cost of Revenue TTM 3.19b) / Revenue TTM)
Gross Margin QoQ = 52.59% (prev 51.92%)
Tobins Q-Ratio = 3.39 (Enterprise Value 41.46b / Total Assets 12.23b)
Interest Expense / Debt = 0.82% (Interest Expense 28.0m / Debt 3.41b)
Taxrate = 8.20% (30.0m / 366.0m)
NOPAT = 1.39b (EBIT 1.51b * (1 - 8.20%))
Current Ratio = 2.25 (Total Current Assets 4.25b / Total Current Liabilities 1.89b)
Debt / Equity = 0.54 (Debt 3.41b / totalStockholderEquity, last quarter 6.37b)
Debt / EBITDA = 1.04 (Net Debt 1.87b / EBITDA 1.80b)
Debt / FCF = 1.34 (Net Debt 1.87b / FCF TTM 1.40b)
Total Stockholder Equity = 6.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.98% (Net Income 1.22b / Total Assets 12.23b)
RoE = 19.97% (Net Income TTM 1.22b / Total Stockholder Equity 6.11b)
RoCE = 15.98% (EBIT 1.51b / Capital Employed (Equity 6.11b + L.T.Debt 3.35b))
RoIC = 14.57% (NOPAT 1.39b / Invested Capital 9.52b)
WACC = 9.88% (E(39.59b)/V(43.00b) * Re(10.67%) + D(3.41b)/V(43.00b) * Rd(0.82%) * (1-Tc(0.08)))
Discount Rate = 10.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.37%
[DCF Debug] Terminal Value 69.27% ; FCFE base≈1.41b ; Y1≈1.41b ; Y5≈1.49b
Fair Price DCF = 61.46 (DCF Value 17.42b / Shares Outstanding 283.5m; 5y FCF grow -0.63% → 3.0% )
EPS Correlation: -29.51 | EPS CAGR: -3.94% | SUE: 0.0 | # QB: 0
Revenue Correlation: -42.00 | Revenue CAGR: -2.23% | SUE: 4.0 | # QB: 2
Additional Sources for A Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle